Hospital Dermatology Research Articles

Propranolol's effects on the sleep of infants with hemangiomas: A prospective pilot study.

To assess propranolol's impact on sleep when used in infants and toddlers with infantile hemangioma (80% under 6months old). Parents and caregivers of infants and toddlers with infantile hemangioma presenting to a tertiary pediatric hospital's dermatology clinic and assessed by their dermatologist as requiring propranolol treatment were invited to participate. All participants completed an extended version of the Brief Infant Sleep Questionnaire (BISQ) prior to propranolol treatment initiation, which acted as the control, and 5weeks after treatment commencement. Objective data were gathered through actigraphy, which utilizes a small wristwatch-like device that measures sleep-wake patterns, for 1week prior to initiation and again 5weeks after commencement. BISQ responses and actigraphy values from the two time points were compared. 55 infants and toddlers (aged 0-2.8years, 80% under 6months) were included. Sleep was reported as only a minor problem by most parents 5weeks after starting propranolol (P=.049). Subgroup analysis of 45 infants <6months old showed no significant difference in sleep while taking propranolol. Whole cohort BISQ data analysis showed a statistically significant increase in night-time sleep (P=.024), and a decrease in the number (P=.003) and duration of daytime naps (P=.025) following commencement of propranolol. Actigraphy data completed in 10 infants showed no significant difference in sleep quality before and 5weeks after commencing propranolol. Propranolol did not significantly impair sleep quality and pattern in our cohort of infants and toddlers with infantile hemangioma. Most parents considered the impact on sleep to be only a minor problem.

Psychological burden of psoriatic patients in a German university hospital dermatology department.

Psoriasis has a strong impact on patients' lives and is closely linked to psychiatric disorders such as depression, anxiety and substance-related disorders, especially dependence on alcohol and nicotine. The aim of our study was to systematically assess the psychiatric comorbidity and possible associations between psychological factors, disease severity and dermatology-related quality of life in psoriatic patients from a high-need university hospital dermatology department. Consecutive psoriatic patients (new and permanent patients) at the Department of Dermatology, University Hospital Essen, Germany, were asked to fill out a paper-based questionnaire. In the first part of the questionnaire, baseline demographics, pre-existing mental disorders and data on substance abuse were collected. In the second part of the questionnaire, mental and physical health was explored using different validated self-rating tests. The current Psoriasis Area and Severity Index (PASI) was documented by a dermatologist. Patients with signs of mental disorders were offered an appointment with a board-certified psychiatrist. Between August 2016 and February 2019, 228 consecutive psoriatic patients (138 men [60.5%], 90 women [39.5%]; mean age, 48.3years [standard deviation, 13.6; range, 18-80]) participated in the study. Approximately 50% of the patients had evidence of suffering from mental health problems, mostly depression and anxiety, as well as alcohol dependence. Patients with a PASI of 3 or more showed a statistically significant reduced Dermatology Life Quality Index (DLQI) and a significantly impaired psychological as well as physical quality of life. DLQI correlated with all psychological test results. The data indicate a significant psychological burden in a tertiary psoriatic population. Our findings underscore the importance of screening psoriatic patients for psychiatric disorders, with a focus on depression, anxiety as well as alcohol and nicotine dependence, in a multidimensional approach involving psychiatrists and psychologists.

Evaluation of the Dermatological Life Quality Index, sexual dysfunction and other psychiatric diseases in patients diagnosed with vitiligo with and without genital involvement.

Because skin lesions affect self-image, vitiligo affects an individual's emotional and psychological well-being, sexual life and relationships with other people. The literature contains a limited number of studies regarding the localization of vitiligo with respect to its effect on certain variables. To investigate the effects of the presence or absence of genital involvement in vitiligo on sexual dysfunction, dermatological quality of life (QoL), and susceptibility to other psychiatric disorders such as anxiety and depression. In total, 90 patients who were admitted to the dermatology outpatient clinic of a tertiary university hospital; the patients included 30 patients with vitiligo with genital involvement, 30 patients with vitiligo without genital involvement and 30 controls (HCs). All groups were evaluated with the Dermatological Life Quality Index (DLQI), Hospital Anxiety and Depression Scale (HAD), Arizona Sexual Experience Scale (ASEX) and Golombok-Rust Inventory of Sexual Satisfaction (GRISS). The HC groups exhibited lower total scores on the DLQI, HAD total score, ASEX and GRISS compared with the vitiligo groups (P<0.05). No statistically significant difference was found between the vitiligo group with genital involvement and the vitiligo group without genital involvement in terms of DLQI, and total scores for HAD, ASEX and GRISS (P>0.05). The presence or absence of genital involvement in vitiligo did not have dissimilar effects on the individual's QoL, or their sexual and psychological state.

Pilot Study of a Customized Nanotextile Wet Garment Treatment on Moderate and Severe Atopic Dermatitis: A Randomized Clinical Trial

H He, MJ Koh, HY Lee, SB Ang. Pediatr Dermatol . 2020;37(1):52–57 To compare the use of nanotextile (100% nanopolyester) and viscose rayon (Tubifast) garments for wet wrap therapy (WWT) thereby demonstrating nanotextile as a comparable alternative to the conventional material, viscose. The study included infants and children younger than 18 years of age with moderate to severe atopic dermatitis (AD) from the KK Women’s and Children’s Hospital inpatient ward and dermatology outpatient clinics in Singapore City, Singapore. Exclusion criteria included those with active skin infection, on immunotherapy, and phototherapy. Patients were recruited between March 4, 2017 to August 8, 2017. Enrolled patients were randomized to undergo viscose or nanotextile WWT in addition to …

18307 Antibiotic prescribing practice for acne within a UK hospital dermatology department

Acne is a common inflammatory skin condition, characterised by blockage and inflammation of the pilosebaceous unit. Treatment is aimed at reducing severity of lesions and to limit scarring, with topical and oral antibiotics remaining popular initial treatment options. There is growing concern regarding antimicrobial resistance and recent initiatives advise antibiotic stewardship when treating acne. These include avoiding antibiotic monotherapy, limiting the use of antibiotics for short periods, and combining oral antibiotics with topical retinoids and benzoyl peroxide.

Dermatology Reports: A journal coming to a new life.

Dermatology Reports is an open access journal published online since 2009. It is devoted to any aspects of dermatology and it is indexed in most citation databases, such as Medline and Embase. Recently, the journal changed, in a sense, its life by becoming the Official Journal of the Italian Association of Hospital Dermatologists (ADOI - Associazione Dermatologi-Venereologi Ospedalieri Italiani e della sanità pubblica) and, thanks to an agreement with ADOI, of the Italian Melanoma Intergroup (IMI). (...)

Quality of life in black African patients with keloid scars.

A keloid scar is a benign skin tumor and we aimed to assess the Quality of Life (QoL) of black Africans with keloid scars based on the Dermatology Life Quality Index (DLQI). We conducted a cross-sectional descriptive study in the department of dermatology of the teaching hospital of Treichville in Ivory Coast. We recruited 132 patients with keloid and 3612 dermatoses without keloid: The prevalence was 3.50% (132/3753). We included 120 patients aged from 16 to 63 years old, the sex ratio was 0.46 (38/82) and the mean age was 34.20 years. Keloid scars were mostly secondary to skin trauma in 30.00 % and infection in 21.67%. The commonest site was the ear in 29.17 %. We reported Keloid with pain in 53.33% and pruritus in 95.00%. We observed psychological impact in 65.83%. The DLQI scores were moderate and high in 61.66 %. QoL was impacted significantly when keloid was associated with pain (p=0.046), pruritus (p=0.81) and functional disorders (p=0.29). The DLQI score could be a valuable tool to assess QoL in black African patients with keloid, for better treatment option.

Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis

Demonstrating the value of therapies from a patient's perspective is increasingly important for patient-centered care. To compare patient-reported outcomes (PROs) with risankizumab vs ustekinumab and placebo in psoriasis symptoms, health-related quality of life (HRQL), and mental health among patients with moderate to severe psoriasis. The UltIMMa-1 and UltIMMa-2 studies were replicate 52-week phase 3, randomized, multisite, double-blind, placebo-controlled and active comparator-controlled trials conducted in 139 sites (including hospitals, academic medical centers, clinical research units, and private practices) globally in Asia-Pacific, Japan, Europe, and North America. Adults (≥18 years) with moderate to severe chronic plaque psoriasis with body surface area (BSA) involvement of 10% or more, Psoriasis Area Severity Index (PASI) scores of 12 or higher, and static Physician's Global Assessment (sPGA) scores of 3 or higher were included. In each trial, patients were randomly assigned (3:1:1) to 150 mg of risankizumab, 45 mg or 90 mg of ustekinumab (weight-based per label) for 52 weeks, or matching placebo for 16 weeks followed by risankizumab. Integrated data from 2 trials were used to compare Psoriasis Symptom Scale (PSS) (total score and item scores for pain, redness, itchiness, and burning), Dermatology Life Quality Index (DLQI), 5-level EuroQoL-5D (EQ-5D-5L), and Hospital Anxiety and Depression Scale (HADS), at baseline, week 16, and week 52. A total of 997 patients with moderate to severe chronic plaque psoriasis were analyzed. Across all arms, the mean age was 47.2 to 47.8 years and 68.3% (136/199 for ustekinumab) to 73.0% (146/200 for placebo) were men. Patients' characteristics and PROs were comparable across all treatment arms at baseline (n = 598, 199, 200 for risankizumab, ustekinumab, and placebo, respectively). At week 16, a significantly greater proportion of patients treated with risankizumab than those treated with ustekinumab or placebo achieved PSS = 0, indicating no psoriasis symptoms (30.3% [181/598], 15.1% [30/199], 1.0% [2/200], both P < .001), and DLQI = 0 or 1 indicating no impact on skin-related HRQL (66.2%, 44.7%, 6.0%, P < .001). Significantly greater proportions of patients treated with risankizumab achieved minimally clinically important difference (MCID) than ustekinumab or placebo for DLQI (94.5% [516/546], 85.1% [149/175], 35.6% [64/180]; both P < .001), EQ-5D-5L (41.7% [249/597] vs 31.5% [62/197], P = .01; vs 19.0% [38/200], P < .001), and HADS (anxiety: 69.1% [381/551] vs 57.1% [104/182], P = .004; vs 35.9% [66/184], P < .001; depression: 71.1% [354/598] vs 60.4% [96/159], P = .01; vs 37.1% [59/159], P < .001). At week 52, improvements in patients treated with risankizumab compared with those treated with ustekinumab were sustained for PSS, DLQI, and EQ-5D-5L. Risankizumab significantly improved symptoms of moderate to severe psoriasis, improved HRQL, and reduced psychological distress compared with ustekinumab or placebo. ClinicalTrials.gov Identifiers: NCT02684370 (UltIMMa-1) and NCT02684357 (UltIMMa-2).

Adherence with dermatology consultant recommendations: A retrospective study of 417 hospital dermatology consultations

Adherence with dermatology consultant recommendations: A retrospective study of 417 hospital dermatology consultations

Examination of androgenetic alopecia with serum biomarkers.

Androgenetic alopecia (AGA) is the most common type of hair loss and affects approximately 50% of the male population. In the present study, to investigate microinflammation, perifollicular fibrosis, and oxidative stress in AGA cases, some serum biomarker levels were measured and evaluated. Serum samples were drawn from patients (n=58) and control (n=30) groups referring to Atatürk Training and Investigation Hospital Dermatology Outpatient clinic. In serum samples, NF-κB, TNF-α, TGF-β1, thioredoxin, nitric oxide, TOS, TAS, and thiol disulfide homeostasis (native thiol, total thiol, disulfide) were measured and evaluated. In patients with AGA, NF-κB (P=.005), TNF-α (P=.008), TGF-β1 (P=.028), thioredoxin (P=.004), nitric oxide (P<.001), and TOS (P<.001) serum levels were found to be significantly higher than those in control group, while TAS (P=.003), native thiol (P<.001), total thiol (P<.001), and disulfide (P<.001) serum levels were found to be significantly lower. According to the results of the present study, it was concluded that in that AGA androgens lead to oxidative stress by increasing free oxygen radicals, which accelerates hair loss by causing microinflammation and fibrosis. The recognition of the effect of androgens and associated factors on the hair follicle cycle is essential for the development of new and effective treatment methods.

Hospital dermatology: an emerging subspecialty and its contributions to medical care.

Hospital dermatology: an emerging subspecialty and its contributions to medical care.

Investigation of detection capacities of laboratories in sexually transmitted disease surveillance areas in China

Objective: To understand the detection capacities of the laboratories in medical institutions in national sexually transmitted disease (STD) surveillance areas in China. Methods: A cross-sectional study was conducted to investigate the applications of STD tests in laboratories of the medical institutions in 105 STD surveillance areas in China, the proportion of each STD test application was calculated and the differences among medical institutions were compared. Results: In 752 medical institutions, the proportions of Treponema pallidum serological test and non-Treponema pallidum serological test applications were 97.5% (733/752) and 91.4% (687/752), respectively. The proportions of gonococcal culture and Chlamydia trachomatis nucleic acid test applications were 48.4% (364/752) and 23.4% (176/752), respectively. The application proportions of all tests for herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) were less than 40%. In medical institutions at provincial, prefectural and county levels, the application proportions of serological tests of Treponema and non-Treponema were all more than 90%, and the application proportions of gonococcal culture were 66.9% (83/124), 46.9% (197/420) and 47.4% (82/173) respectively, the application proportions of Chlamydia trachomatis nucleic acid test were 29.0% (36/124), 25.0% (105/420) and 19.7% (34/173) respectively. The application proportions of syphilis and gonorrhea tests and chlamydia nucleic acid test in public medical institutions were higher than those in private/joint venture medical institutions and higher in dermatological specialized hospitals than those in general hospitals and maternal and child health centers. The application proportions of STD tests in medical institutions in eastern China and central southern China were generally higher than those in other areas, and the lowest was found in northwestern China. Conclusions: Serological tests for syphilis have been carried out widely in medical institutions in all STD surveillance areas in China, but there were insufficient use of tests for gonococcal culture and Chlamydia trachomatis nucleic acid. The application proportions of STD tests vary in medical institutions at different levels and with different types and ownerships, and the development of STD testing is unbalanced in different areas. It is necessary to strengthen the capacity building of gonococcal culture and Chlamydia trachomatis nucleic acid test, and strengthen the capacity building of STD testing in grassroots, private/joint venture medical institutions and those in underdeveloped western areas.

Role of Alpha Trypticase Enzyme, Total IgE, Specific IgE &amp; IgG4 In Patients with Food Allergy

Background: Foodallergy is an abnormal adverse immune response to exposure and consumption of a variety of food containing allergens in individuals inherited atopic gene. Different types of food materials are imposed on food hypersensitivity like egg, milk, dairy products, nuts, and other foodstuffs. Different tests are used to diagnose and follow up food allergies like total IgE, Specific IgE and Skin test. Objectives: This study aimed to investigate the importance of IgG4 and Alpha Typticase parameters besides total and specific IgE in diagnosis food allergy cases in patients. Patients &Methods: The study was conducted during the period from October 2019 to January 2020 at Ramadi Teaching Hospital and Microbiology Department, College of Medicine, University of Anbar. Seventy-five (75) Patients form both sexes, adults and children were showing signs and symptoms consistent with food allergy were attending Allergy Section at Ramadi Teaching Hospital and Private Allergy and Dermatology Clinics at Ramadi city, each patient was examined and followed by a senior physician. serum from each was investigated for total IgE, Specific IgE, IgG4, and serum Trypticase contents. Fifty normal individuals resembling the patient's group were considered as the Control group and the same investigations were done for them. Data were analyzed using SPSS system. Results: Adult patients above 30 years old were showing the highest ratio of food allergy (52.0%) while the lowest ratio (16%) was found among children with predominance in females (54.7%) Higher values of IgE were found among patients (38.7%) with mean value more than 200IU/ml. Serum IgG4 was elevated in those with food allergy with increased total IgE in the patient group. Higher Tryptase enzyme means values (17.21 ng / ml) were found in patients sera than control individuals (9.4 ng / ml) with no effect of gender. Eight (8, 38%) of sera were showing positive specific IgE in children while eighteen (18, 71%) of adult sera were positive for specific IgE . Child patients were showing positive results for Milk, Egg white, Cacao, Nuts, and Wheat, while adults were found positive for pepper, Barely, Tomato, Citrus, and Broad beans. Conclusion: Food allergy represents a common health problem at any age group and mostly in adult and child females. Total serum IgE, IgG4, and Serum tryptase were elevated in these patients affected with a variety of food allergens. So They are good parameters for food allergy.

Attitudes about and practices for skin cancer prevention among patients with dermatological issues in Hanoi, Vietnam: a cross-sectional study

BackgroundRaising awareness and educating people regarding practices for skin cancer or melanoma prevention are critical in the context of the adversely increasing effects of global climate change. This study aimed to explore the knowledge, attitudes, and practices regarding skin cancer prevention and to determine the associated factors to knowledge, attitudes, and practices among dermatological patients in Vietnam.MethodsThis cross-sectional study included 590 dermatological patients between 18 and 82 years of age, who received an examination or treatment from the National Hospital of Dermatology in Hanoi, Vietnam, from September to December 2018. The respondents’ attitudes on skin cancer and cancer prevention were assessed via face-to-face interviews with a structured questionnaire conducted by trained interviewers.ResultsOf the 590 respondents, the majority of people had correct responses to the question regarding skin cancer knowledge. Among the total participants, 39.8% thought that they were at risk of skin cancer, and 13.8% believed their occupation increased their skin cancer risk. The majority of respondents used hats (94.9%) and sunscreen skin coats (89.5%) and went into the shade (86.3%) when exposed to the sun. Women were less likely to be aware of their skin cancer risk but were more likely to practice prevention behaviors.ConclusionOur results show that dermatological patients have acceptable knowledge towards skin cancer prevention, but still need to change their behavior to prevent the risk of skin cancer. This study highlights the importance of education to raise awareness regarding skin cancer in order to promote practice prevention strategies for skin cancer in Vietnam.

Photodynamic Therapy Using HMME for Port-Wine Stains: Clinical Effectiveness and Sonographic Appearance.

This study aims at exploring the clinical efficacy and sonographic changes of photodynamic therapy (PDT) using Hematoporphyrin Monomethyl Ether (HMME) for the treatment of port-wine stains (PWS). Forty-five patients with PWS were recruited between March 2017 and June 2018 from the Department of Dermatology of The Third Affiliated Hospital of Soochow University. Five cases were of the pink type, thirty-nine cases were of the purple-red type, and one case was of the thickened type. All patients received three treatment sessions of PDT. After covering normal skin outside the treated area, patients received an intravenous injection of 5 mg/kg HMME within 20 minutes. The affected areas were exposed to a 532 nm LED light and were kept vertically at a distance of 10 cm. The irradiation energy density was set between 80 and 110 J/cm2 in 15-minute sessions. Intermittent power density adjustment was performed at a rate of 5 mW/cm2, and the treatment was withheld when the endpoint reaction appeared. Three follow-ups were performed before and after treatment, respectively, and the efficacy, thickness, and density of skin before and after treatment were evaluated with high-frequency ultrasound. The overall efficacy rate was 97.78% in forty-five cases after treatment for three sessions. Efficacy was related to age (P = 0.029) and lesion severity (P < 0.001). There were significant differences in the efficacy between the groups of <18 years old, 18-29 years old, and >29 years old (P = 0.029). A marked decrease in the numbers of distorted enlarged blood vessels per unit of the lesion was observed under high-frequency ultrasound. There were significant differences in skin thickness and skin density before and after treatment (F = 14.528, 5.428, P < 0.001). The swelling was reported to varying degrees in the treated areas in 23 patients with cheek lesion and in 6 frontal lesions. Hyperpigmentation after inflammation was observed in four patients that faded spontaneously after two months. In conclusion, photodynamic therapy for the treatment of PWS using HMME is effective and safe with few adverse reactions. Moreover, monitoring the changes in skin thickness and density of lesion tissue using high-frequency ultrasound can objectively evaluate the clinical efficacy of HMME photodynamic therapy and provide the basis for the formulation of individualized photodynamic therapy.

Herpes Virus, Causes of Infections and Preventive Methods

Herpes simplex virus (HSV) usually has two groups, including HSV1 and HSV2. HSV1 often causes skin&#x0D; and mucous membranes in the upper part of the body like the nose and mouth. HSV2 group causes skin&#x0D; disease in the genital mucosa. This type of virus is quite common in our life today, has a great influence on&#x0D; human health and needs certain attention. The paper was based on previous research as well as conducted&#x0D; with the collected data from surveys of 40 patients infected with herpes simplex virus among 250 people&#x0D; who were asked at two dermatology hospitals in southern Vietnam between March and April 2019. Thanks&#x0D; to the analysis method developed by Hancock, this research aims to verify some causes of infecting herpes&#x0D; simplex viruses, effective treatment methods as well as ways to prevent this kind of disease in order to&#x0D; enhance common knowledge for the prosperity of human beings. Accordingly, some solutions have been&#x0D; recommended with the purpose of making our world a better place to live.

Correlation between serum vitamin D levels and severity of vitiligo

Objective To correlate between serum vitamin D levels and severity of vitiligo. Background Vitiligo is an acquired depigmentary disorder that affects more than 0.5–1% of the worldwide population. Vitamin D has been implicated in the pathogenesis of various autoimmune diseases. The correlation between vitiligo and vitamin D is discussed in this study. Patients and methods This case–control study was conducted on 60 patients with vitiligo and 60 age-matched and sex-matched healthy individuals. All patients were recruited from the Outpatient Clinic of Dermatology and Andrology Department of Shebeen El-Kom University Hospital between 1 May 2018 and 31 August 2018. Blood samples were taken, and serum levels of vitamin D were measured by enzyme-linked immunosorbent assay technique. Serum levels of vitamin D were statistically analyzed in relation to Vitiligo Area Severity Index (VASI) score using Spearman coefficient test. Results The patients had higher serum vitamin D levels than the controls with highly significant difference (P Conclusion There was no significant correlation between vitamin D levels and VASI score. Future larger controlled studies are required to obtain a wider assessment of the relationship between vitamin D level and vitiligo disease severity.

An adult co-presented with varicella and herpes zoster caused by varicella zoster virus genotype J, China: a case report

BackgroundVaricella zoster virus (VZV) causes varicella primarily in childhood, and some rare adults also report varicella. Herpes zoster mainly occurs in adults by endogenous reactivation of latent VZV. Until now, varicella and herpes zoster have seldom been reported simultaneously in one patient. Here, we report a rare case co-presenting with varicella and herpes zoster in a Chinese adult.Case presentationA 44-year-old Chinese man suffered papules and vesicles with pain on the left ear. Five days after onset, he was admitted to the Department of Dermatology of The Third Hospital of Xiamen. Physical examination revealed that small vesicles surrounded by erythema had developed on his trunk, back and neck, and unilateral papules and vesicles in ribbons had also developed on the left ear. This patient was excluded from human immunodeficiency virus and Treponema pallidum infections by ELISA antibody tests. Laboratory tests revealed that the ratio of eosinophils (0.1%) and eosinophil count (0.0 × 109/L) were significantly downregulated. Treatment with valacyclovir, ebastine, mecobalamine, pregabalin and calamine lotion for 5 days was effective therapy for varicella and herpes zoster. Polymerase chain reaction for vesicular fluids from varicella and herpes zoster was positive for VZV, and further phylogenetic analysis and single nucleotide polymorphism variations confirmed that the VZV genotype was type J (clade 2).ConclusionsThis rare case highlights awareness of varicella and herpes zoster caused by VZV infection in adults. Our report provides novel insight into the rare clinical presentation of VZV genotype J.

Efficacy and safety of IO103 a novel anti PD-L1 vaccine in basal cell carcinoma.

e22070 Background: Basal cell carcinoma (BCC) is the most frequent malignancy. Case reports have described effect of immune checkpoint blocking antibodies (ICB) against PD-1 in BCC (Cannon et al. 2018, Chang et al. 2017, Ikeda et al. 2016, Winkler et al. 2017). Autoimmune side effects of ICB are well known and limits a wider use in BCC. IO103 is a peptide vaccine against major programmed death (PD) ligand 1 (PD-L1). In a first-in-man study of IO103 in patients with multiple myeloma (NCT03042793) regression of co-existing BCC was observed in two patients which prompted the current study. Methods: A single arm phase IIa study of subcutaneous IO103 (q2w six times followed optionally by q4w an additional 3 times) with the adjuvant Montanide for patients with BCC (NCT03714529). Eligible patients had at least one biopsy verified BCC suitable for sequential biopsies, and no severe autoimmune comorbidity. The primary endpoints were categorical clinical responses of target tumors, percent change in largest diameter of target tumor and immune responses to the vaccine. Secondary endpoint was safety. One tumor per patient was designated target tumor, if more than one tumor the remaining were designated non-target tumors. Only target tumors were sequentially biopsied during vaccinations. Results: Ten patients were included at the department of Dermatology, Herlev and Gentofte Hospital, Denmark between November 19th, 2018 and October 21st, 2019. Based on target lesion assessment, one patient achieved partial response. Two additional patients achieved CR in non-target lesions, including one lesion that had recurred after previous surgery. Categorical clinical responses are given in table. Adverse events were max CTCAE Grade 2 and related events were only CTCAE Grade 1 reversible reactions. Vaccine induced immune responses against PD-L1 were detected in blood samples from eight of ten patients and vaccine specific skin-infiltrating lymphocytes from five of eight tested patients. Conclusions: In this exploratory study, one target tumor achieved partial response. Nonetheless, the two clearances and one partial response of non-target tumors suggest that IO103 may be effective against BCCs. The vaccine was well tolerated. Understanding the underlying molecular mechanisms would be needed to select patients for further studies with IO103. Clinical trial information: NCT03714529. [Table: see text]

Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: A multicenter, randomized, double-blind, double-dummy, pilot study

Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: A multicenter, randomized, double-blind, double-dummy, pilot study